ADDISON, TX / ACCESSWIRE / March 16, 2015 / Wound Management Technologies, Inc. (WNDM) ("Company"), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Wound Care Innovations ("WCI"), a subsidiary of the Company, received its inaugural order from Mexico, where WCI is registered and signed a distribution agreement with VISECA Desarrollo Inmobiliario SA de CA ("VISECA"), a healthcare distributor in Mexico. CellerateRX(R) received COFEPRIS approval from the Mexico Ministry of Health.
Cesar Camargo, General Manager of VISECA, stated, "We are excited to partner with Wound Care Innovations on the distribution of CellerateRX(R) to the country of Mexico. Diabetes affects almost 50% of the Mexican population and it has cost the government billions to manage the diabetes-related problems. With what we have seen in terms of the clinical data and cost savings, we anticipate the physicians in Mexico introducing the product into their practice at an accelerated rate."
In addition to Mexico, Wound Care Innovations is also registered and has signed distribution agreements for CellerateRX(R) in Nigeria, Saudi Arabia, South Africa, and Trinidad. WCI also has registrations in process in many additional countries.
Robert Lutz, Jr., Chairman and Chief Executive Officer, commented, "Diabetes and the health risks associated with the disease continue to be on the rise worldwide. The opportunity to enter these international markets further supports the growth trajectory of the Company and allows us to continue to execute on our corporate strategic growth initiatives. We believe that the clinical efficacy of CellerateRX(R), paired with its cost efficiency, fills an unmet need in these countries and we look forward to further expansion as we continue to pursue registration and distribution in other countries."
About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.